Pouch, the head of the National Institute of Allergy and Infectious Diseases, who leads the development of the corona vaccine in the United States, said the vaccine could be available earlier than expected if the vaccine clinical trial yields overwhelmingly positive results.
In an interview with a media, Pouch said that the independent'Data and Safety Monitoring Committee' has the authority to terminate the clinical trial ahead of time according to the interim results of the corona vaccine clinical trial.
In the U.S., with two vaccine candidates currently receiving 30,000 volunteers, phase 3 clinical trials are in progress, and the prospect of conclusions at the end of the year was dominant.
(Photo = Getty Image Korea)